Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ralph Lauren Corp (RL) vs Viatris Inc (VTRS) Price & Performance

Ralph Lauren CorpTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Ralph Lauren Corp vs Viatris Inc — how do they compare? Ralph Lauren Corp trades at $387.44 (market cap $22.79B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Ralph Lauren Corp and Viatris Inc are close in size by market cap, and Viatris Inc pays the higher dividend (2.73%). Which is the better fit depends on your goals.

RLVTRS
Market Cap
$22.79B$20.50B
Sector
Consumer CyclicalHealth
52-Week High
$414.25$17.59
52-Week Low
$283.34$8.74
Enterprise Value
$23.73B$32.71B
Dividend Yield
0.98%2.73%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ralph Lauren Corp

Ralph Lauren (RL) trades at $382.93, up 0.65% today, with strong fundamentals including 11.6% net margin and 34.66% ROE. Recent earnings beats and a $1.00 dividend signal financial health, though technical indicators show bearish momentum near resistance at $383. Revenue growth to $7.08B in 2025 and a $445.71 analyst target suggest upside potential.

The stock offers growth through premium branding and digital expansion, but faces risks from consumer discretionary weakness and high valuation multiples. Analyst consensus is strongly bullish (66% buy ratings), yet technical pressure and macroeconomic sensitivity warrant caution for near-term entry points.

Viatris Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About Ralph Lauren Corp

Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.

Read more on RL

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS